Johnson & Johnson (J&J; NYSE: JNJ) subsidiary Janssen has provided an update on an ongoing Phase Ib/II study cohort assessing the safety and pharmacokinetics of the bispecific antibody (BsAb) Rybrevant (amivantamab) in combination with tyrosine kinase inhibitor (TKI) lazertinib and chemotherapy for the treatment of relapsed/refractory EGFR-mutated non-small cell lung cancer (NSCLC). The combination therapy demonstrated an objective response rate (ORR) of 50% and a median progression-free survival (PFS) of 14 months, with the median duration of response not reached after 13.1 months.
Therapeutic Potential of Rybrevant in NSCLC
Rybrevant has received global approvals for the treatment of NSCLC with EGFR exon 20 insertion mutations, positioning it as a significant player in the targeted therapy landscape for this specific patient population. The positive results from this study further highlight the potential of Rybrevant in combination with other therapies to improve outcomes for patients with EGFR-mutated NSCLC.
Ongoing Trials and Future Prospects
In addition to this study, Rybrevant is also undergoing several other trials in NSCLC, exploring its efficacy and safety in various settings and patient populations. These trials aim to expand the understanding of Rybrevant’s role in NSCLC treatment and potentially increase its applicability in clinical practice.-Fineline Info & Tech
